Addressing unmet needs for inherited neuromuscular diseases
angilma1
Thu, 11/21/2024 – 12:45
Read more about Addressing unmet needs for inherited neuromuscular diseases
PrintPDF
Entries by angilma1
Negative impact of the IRA on patient access to innovative treatments
angilma1
Thu, 08/15/2024 – 14:46
Read more about Negative impact of the IRA on patient access to innovative treatments
PrintPDF
Novartis statement on Maximum Fair Price for Entresto
angilma1
Thu, 08/15/2024 – 14:36
Read more about Novartis statement on Maximum Fair Price for Entresto
PrintPDF
Novartis Financial Results – Q2 2024
angilma1
Mon, 07/15/2024 – 11:49
Read more about Novartis Financial Results – Q2 2024
PrintPDF
A legacy of blood cancer innovation
angilma1
Fri, 05/31/2024 – 18:01
Read more about A legacy of blood cancer innovation
PrintPDF
Novartis receives FDA Breakthrough Therapy designation for Scemblix® in 1L CML
angilma1
Fri, 05/10/2024 – 10:14
Read more about Novartis receives FDA Breakthrough Therapy designation for Scemblix® in 1L CML
PrintPDF
Novartis Financial Results – Q1 2024
angilma1
Thu, 04/18/2024 – 09:55
Read more about Novartis Financial Results – Q1 2024
PrintPDF
Novartis Appoints Sloan Simpson as Global Head of Investor Relations
angilma1
Thu, 02/15/2024 – 09:51
Read more about Novartis Appoints Sloan Simpson as Global Head of Investor Relations
PrintPDF
Novartis at the J.P. Morgan Healthcare Conference 2024
angilma1
Thu, 01/04/2024 – 15:51
Read more about Novartis at the J.P. Morgan Healthcare Conference 2024
PrintPDF
Violence against innocent people runs counter to our work to improve human health
angilma1
Wed, 10/18/2023 – 17:37
Read more about Violence against innocent people runs counter to our work to improve human health
PrintPDF